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Abstract
Introduction: Although access to highly active antiretroviral therapy (HAART) has prolonged survival and improved
life quality, HIV-infected patients with severe immunosuppression or comorbidities may develop complications that
require critical care support in intensive care units (ICU). This study aimed to describe the etiology and analyze the
prognostic factors of HIV-infected Taiwanese patients in the HAART era.
Methods: Medical records of all HIV-infected adults who were admitted to ICU at a university hospital in Taiwan
from 2001 to 2010 were reviewed to record information on patient demographics, receipt of HAART, and reason
for ICU admission. Factors associated with hospital mortality were analyzed.
Results: During the 10-year study period, there were 145 ICU admissions for 135 patients, with respiratory failure
being the most common cause (44.4%), followed by sepsis (33.3%) and neurological disease (11.9%). Receipt of
HAART was not associated with survival. However, CD4 count was independently predictive of hospital mortality
(adjusted odds ratio [AOR], per-10 cells/mm
3 decrease, 1.036; 95% confidence interval [CI], 1.003 to 1.069).
Admission diagnosis of sepsis was independently associated with hospital mortality (AOR, 2.91; 95% CI, 1.11 to
7.62). A hospital-to-ICU interval of more than 24 hours and serum albumin level (per 1-g/dl decrease) were
associated with increased hospital mortality, but did not reach statistical significance in multivariable analysis.
Conclusions: Respiratory failure was the leading cause of ICU admissions among HIV-infected patients in Taiwan.
Outcome during the ICU stay was associated with CD4 count and the diagnosis of sepsis, but was not associated
with HAART in this study.
Introduction
After the introduction of highly active antiretroviral
therapy (HAART), the life expectancy of HIV-infected
patients has significantly increased and the incidence of
illnesses associated with AIDS markedly decreased [1].
Nevertheless, HIV-related complications that may
require critical care support continue to occur in HIV-
infected patients who are unaware of their HIV serosta-
tus and do not initiate HAART and appropriate antimi-
crobial prophylaxis, or who fail to respond to HAART
with virological and immunologic failures. These
patients may also require critical care because of other
co-morbidities such as hepatitis co-infections, alcohol-
ism, or chronic obstructive pulmonary disease [2].
Although respiratory failure and Pneumocystis jirovecii
pneumonia have declined in the HAART era compared
with the pre-HAART era, they remain the most com-
mon diagnoses of HIV-infected patients who were
admitted to ICUs [3,4]. Compared with patients in the
pre-HAART era, patients in the HAART era are more
likely to have life-threatening sepsis, neurologic disor-
ders, and complications of end-stage liver disease [4-6].
Several studies have shown that the advent of HAART
not only improved the survival of HIV-infected patients
admitted to ICU [7-10], but also changed the etiology of
admissions to the ICU whereby fewer patients were
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[10-13]. However, the patient populations included in
the studies examining the benefits of HAART are het-
erogeneous in exposure to HAART, durations of
HAART, and timing of HAART [14-20]. The results on
survival benefits of HAART are inconsistent across the
reported studies in the HIV-infected patients who are
already admitted to ICU.
In the era of HAART, prognostic factors of mortality
for HIV-infected patients admitted to ICU do not
appear to have significant changes [8,12,14-20]. These
factors include the severity of acute illness (as assessed
by Acute Physiology and Chronic Health Evaluation II
(APACHE II) score, Simplified Acute Physiology Score
II (SAPS II), or Sequential Organ Failure Assessment
(SOFA) score), presence of organ failure (requirement of
mechanical ventilator support, shock, renal failure), CD4
lymphocyte count, hospital-to-ICU interval, and serum
albumin level. However, these reports mostly came from
North America, Latin America, and European countries
that enrolled largely white, black, and Hispanic people.
It remains unknown whether HIV-infected patients in
the Asia-Pacific countries who are admitted to the ICU
share the same etiologies and prognostic factors.
In this study, we aimed to describe the etiologies of
ICU admissions of HIV-infected patients in a university
hospital in Taiwan and to examine the prognostic fac-
tors of hospital mortality in the era of HAART. The
results of our study will be compared with those of
other published studies in HIV-infected patients
admitted to ICUs in the HAART era.
Materials and methods
Study population
This retrospective cohort study was conducted in the
National Taiwan University Hospital, the largest desig-
nated hospital to provide inpatient and outpatient HIV
care in Taiwan, to enroll all HIV-infected patients aged
18 years or greater who were admitted to the medical
and surgical ICU from 1 January, 2001 to 28 February,
2010. The Research Ethics Committee of the hospital
approved the study protocol and waived the need for
informed consent.
HAART was introduced into Taiwan in April 1997
and all HIV-infected patients have free-of-charge access
to antiretroviral therapy according to local treatment
g u i d e l i n e sa n di n p a t i e n ta n do u t p a t i e n tc a r et h a ti s
related to HIV infection at designated hospitals and
clinics around Taiwan. The medical costs, including
antiretroviral therapy and laboratory investigations such
as determinations of CD4 lymphocyte count and plasma
HIV RNA load, are totally reimbursed by the National
Health Insurance and a special budget of Taiwan Cen-
ters for Disease Control. Regarding the end-of-life
decisions, patients and/or their family can choose not to
receive mechanical ventilation, inotropic agents, cardio-
pulmonary-cerebral resuscitation, or electric shock.
However, when patients are in critical illness, we do not
withdraw mechanical ventilation or inotropic agents that
are already applied on them.
Data collection and definitions
We used a standardized case collection form to record
information on demographics, clinical history, risk fac-
tors for HIV infection, HAART, and CD4 lymphocyte
count and plasma HIV RNA load that were available
within one month of ICU admission. If patients were
readmitted to the ICU during the same hospitalization,
only the data from the first admission were included for
analysis of admission diagnoses and mortality predictors.
Prior HAART use was defined as receipt of at least
two classes of antiretroviral drugs at the time of hospital
admission [21]. Laboratory data within three days of
ICU admission (usually within 24 hours) were recorded.
Organ failure status (requirement of mechanical ventila-
tor support, renal replacement, or shock) and APACHE
II scores on ICU admission were also recorded [22].
Shock status was considered if use of vasopressors was
longer than 24 hours. The primary outcome was hospi-
tal mortality.
Diagnosis of P. jirovecii pneumonia was based on
identification of Pneumocystis in the sputum, bronchoal-
veolar-lavage fluid, or transbronchoscopic or surgical
lung biopsy [23,24]. For patients admitted to ICU with
interstitial pneumonitis that was diagnosed based on
radiographic presentations of ground-glass opacities by
high-resolution computed tomography (HRCT), but
without isolated P. jirovecii, they were also classified as
having interstitial pneumonitis of unknown etiology.
Statistical analysis
Clinical characteristics are reported as medians and
interquartile range (IQR) or numbers and percentages.
Multivariable logistic regression analysis was used to
evaluate patient characteristics associated with hospital
mortality. Variables with P values less than 0.20 in the
univariable analyses were entered into a multivariable
logistic regression model with non-stepwise method.
Final model fit was assessed using the Hosmer-Leme-
show and specification tests. SPSS version 17.0 (SPSS
Inc., Chicago, IL, USA) was performed for statistic ana-
lyses. P values less than 0.05 were considered statistically
significant.
Results
Demographic and clinical characteristics
During the 10-year-study period, there were 145 ICU
admissions for 135 patients. Ten patients were admitted
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majority of the ICU cohort were men (91.1%) and Tai-
wanese (98.5%) (Table 1). The median age was 39 years.
Sexual contact was the main risk factor for HIV trans-
mission. The median interval between first HIV diagno-
sis to ICU admission was 1.23 months (IQR, 0-36
months), and 60 patients (44.4%) were newly diagnosed
as having HIV infection on admission. The median
plasma HIV viral load that was available for 121 patients
was 217,000 copies/ml (IQR, 34,500-631,500 copies/ml),
and the median CD4 lymphocyte count that was
available for 129 patients was 30 cells/mm
3 (IQR, 13-
103 cells/mm
3). Overall, 82 patients (60.7%) received
HAART during the ICU stay: 49 patients (36.3%) receiv-
ing prior HAART at hospital admission, and 12 patients
(8.9%) initiating HAART during the ICU stay.
With respect to the organ failure status, 106 patients
(78.5%) needed mechanical ventilator support, 49
patients (36.3%) needed vasopressors for more than 24
hours after admission to ICU, and 11 patients (8.1%)
received renal replacement therapy during the ICU stay.
The median serum albumin level on ICU admission that
Table 1 Clinical characteristics of 135 HIV-infected patients who were admitted to the ICUs at the National Taiwan
University Hospital from 2001 to 2010
Characteristics 135 patients
Median age (years) 39 (31-50)
Male sex 123 (91.1)
Race/ethnicity
Taiwanese 133 (98.5)
other Asians 2 (1.5)
HIV risk factor
Homosexual 53 (39.3)
Bisexual 7 (5.2)
Injecting drug use 16 (11.9)
Transfusion-related 3 (2.2)
Heterosexual/other/unknown 56 (41.5)
HIV-related characteristics
Newly diagnosed HIV infection 60 (44.4)
Time since HIV diagnosis (month) 1.23 (0-36)
Time since AIDS diagnosis (month) 0.73 (0-26)
Prior HAART at hospital admission 49 (36.3)
Duration of HAART for patients on prior HAART (month)
a 13 (6-48)
HAART initiated during ICU stay 12 (8.9)
HAART use in ICU 82 (60.7)
HIV viral load (copies/ml)
b 217,000 (34,500-631,500)
CD4 lymphocyte count (cells/mm
3)
c 30 (13-103)
Organ failure status
Mechanical ventilator use 106 (78.5)
Shock (use of vasopressors > 24 hours) 49 (36.3)
Renal replacement therapy 11 (8.1)
Time from hospitalization to ICU admission (days) 2 (0-9.0)
Laboratory data
Albumin (g/dL)
d 2.83 (2.40-3.40)
LDH (units/L)
e 966.5 (686.5-1446.25)
APACHE II score 19 (15-25)
in-ICU mortality 50 (37.0)
in-hospital mortality 66 (48.9)
Values are given as median (interquartile) or number (%), unless otherwise indicated.
aData were available for 49 patients with prior HAART at hospital admission.
bData were available for 121 patients.
cData were available for 129 patients.
dData were available for 127 patients.
eData were available for 114 patients.
APACHE II, Acute Physiology and Chronic Health Evaluation II; HAART, highly active antiretroviral therapy; LDH, lactate dehydrogenase.
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3.40 g/dl). The median APACHE II score on ICU
admission was 19 (IQR, 15-25). ICU mortality was 50 of
135 patients (37.0%), and hospital mortality was 66 of
135 patients (48.9%).
Diagnoses of ICU admissions
Respiratory failure was the cause for ICU admissions in
60 of all 135 patients (44.4%; Table 2). Among the
patients with respiratory failure, interstitial pneumonitis
with ground-glass opacity was the most common cause
of respiratory failure (51 patients, 37.8%). P. jirovecii
pneumonia was confirmed in 11 patients (8.1%), and
pathology-proven cytomegalovirus (CMV) pneumonitis
occurred in nine patients (6.7%). Sepsis (including bac-
terial pneumonia) was diagnosed in 45 patients (33.3%),
followed by neurological disease (16 patients, 11.9%) and
postoperative care (five patients, 3.7%).
Predictors of in-ICU and in-hospital mortality
In the univariable analysis of hospital mortality, there
was no difference between survivors and non-survivors
with respect to prior HAART, HAART initiated during
the ICU stay, or HAART use during the stay in the ICU
(Table 3). The factors associated with hospital mortality
in univariable analysis were CD4 lymphocyte count (per
10 cells/mm
3 decrease), admission diagnosis of sepsis,
the interval between hospitalization and ICU transfer of
more than 24 hours, and serum albumin level (per 1 g/
dl decrease; Table 3). In multivariable logistic regression
analysis, the independent predictors of hospital mortality
were CD4 lymphocyte count (per 10 cells/mm
3
decrease) (adjusted odds ratio (AOR), 1.036; 95% confi-
dence interval (CI), 1.003-1.069; P = 0.033), and diagno-
sis of sepsis (AOR, 2.91; 95% CI, 1.11-7.62; P = 0.029).
Kaplan-Meier survival curves for 129 patients stratified
by sepsis and CD4 count less than 50 cells/mm
3 (six
patients without available CD4 counts were excluded)
are showed in Figure 1. Log-rank testing was significant
difference between the four groups (P = 0.003).
Discussion
This study is the first cohort study to analyze the etiolo-
gies of ICU admissions and to investigate the predictors
of mortality in HIV-infected patients in the Asia-Pacific
region. In the current study, respiratory failure was the
leading cause of ICU admissions among HIV-infected
patients, followed by sepsis and neurological disease.
CD4 lymphocyte count and admission diagnosis of sep-
sis are two independent predictors of hospital mortality
in multivariable analysis.
The causes of ICU admissions observed in our study
are not different from those observed in other studies
that were conducted in North America, Latin America,
and European countries [8,10,14-16,18-20,25] (Table 4).
However, the percentage of each etiology differs
between our study and others. In our study, 8.1% of the
patients admitted to ICU had diagnoses of P. jirovecii
pneumonia, and 25.9% of the patients were classified as
interstitial pneumonitis with unknown etiology, which
might be probable cases of P. jirovecii pneumonia when
the radiographic findings and clinical response to speci-
fic anti-pneumocystosis therapy were taken into consid-
eration. Taking definite and probable cases of
pneumocystosis together, it might comprise 34.0% of
the patients, which is more than those of other reports
[8,10,14-16,18-20,25] (Table 4). In addition, the percen-
tage of newly diagnosed HIV infection on admission
(46.2%) is higher, and the median CD4 count (30 cells/
mm
3) is lower than those in other studies (Table 4).
The above observations may be because our hospital is
a referral hospital and the majority of patients admitted
to this hospital were severely immunocompromised and
were not on HAART [26,27]. In our study, 63.7% of the
patients did not receive HAART before hospital
admissions.
In this study, we identified two independent predictors
of hospital mortality in multivariable analysis: CD4 lym-
phocyte count and admission diagnosis of sepsis. Low
CD4 lymphocyte count is associated with suppressed
cellular immunity, and its association with increased
mortality has also been demonstrated in prior studies
[15,20].
The association between sepsis and higher rate of
mortality in the critically ill HIV-AIDS population has
Table 2 Diagnoses of 135 HIV-infected patients admitted
to ICU
Admission diagnosis Number (%) of
admissions
Respiratory failure 60 (44.4)
Interstitial pneumonitis with ground glass
opacity
51 (37.8)
Pneumocystosis 11 (8.1)
CMV (pathology-proven) 9 (6.7)
Interstitial pneumonitis of unknown
etiology
35 (25.9)
Others 11 (8.1)
Sepsis (including bacteria pneumonia) 45 (33.3)
Neurological disease 16 (11.9)
Postoperative care 5 (3.7)
Trauma 3 (2.2)
Metabolic disturbance 2 (1.5)
Cardiac disease 2 (1.5)
Gastrointestinal bleeding 2 (1.5)
Drug overdose 1 (0.7)
Miscellaneous 3 (2.2)
CMV, cytomegalovirus.
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Japiassú AM et al. reported that sepsis is a major deter-
minant of 28-day and six-month mortality in HIV-
infected patients admitted to ICU (adjusted hazard ratio,
3.13 and 3.35, respectively). The above study and our
study both revealed that pneumonia is the most com-
mon site of infection (52% and 55.6%, respectively),
whereas our cohort had cases of fewer primary bactere-
mia (15.6%) and nosocomial infections (37%) [19]. The
screening of HIV infection and high suspicion to sepsis
diagnosis could contribute to decrease mortality in criti-
cally ill HIV/AIDS patients [19,28,29]. The trend of rela-
tively lower mortality for patients with interstitial
pneumonitis with ground-glass opacity may be attribu-
ted to increased alertness to identification of severely
immunocompromised patients who present with charac-
teristic radiographic findings [1,4].
Although early initiation of HAART has been shown
to improve survival in patients with AIDS-related oppor-
tunistic infections [13], it remains debatable whether
initiation of HAART improves the outcome of patients
admitted to ICU owing to factors related to issues of
toxicity, bioavailability, and drug-drug interactions [1].
Several studies, including ours, failed to demonstrate
short-term survival benefit of HAART in those patients
admitted to ICU [16-20], probably because in those
patients with severely depleted CD4 counts, improve-
ment of immunity in terms of increase of CD4 counts
or function cannot be achieved after short term of
HAART. Furthermore, early initiation of HAART in
patients with depleted CD4 counts and opportunistic ill-
nesses, such as tuberculosis, non-tuberculous mycobac-
teriosis, cryptococcosis, and Kaposi’s sarcoma, is
associated with increased risk of immune reconstitution
inflammatory syndrome [13,30], which may increase dif-
ficulties in clinical management and mortality in
resource-limited settings.
Prevalence and trends of antiretroviral drug resistance
mutations may also affect the treatment response to
HAART [31]. In Taiwan, the frequency of HIV-1 iso-
lates harbored one or more primary mutations asso-
ciated with antiretroviral resistance to reverse-
transcriptase inhibitors or protease inhibitors increased
significantly from 6.6% in 1999 to 2003 to 12.7% in
2004 to 2006 (P = 0.003) [32]. In our study, 49 patients
had been taking HAART for a median duration of 13
Table 3 Univariable and multivariable analyses of characteristics associated with hospital mortality
Characteristics Univariable analysis Multivariable analysis
Odds ratio
(95% CI)
P
value
Odds ratio
(95% CI)
P
value
Age (per 10-year increase) 1.15 (0.88-1.51) 0.3
Male 2.03 (0.58-7.10) 0.27
HIV risk factor 0.8
MSM reference
Bisexual 0.78 (0.16-3.82) 0.8
Injecting drug use 0.62 (0.20-1.96) 0.4
Transfusion-related 2.08 (0.18-24.31) 0.6
Heterosexual/other/unknown 1.12 (0.53-2.37) 0.8
HIV-related characteristics
Newly diagnosed HIV infection 1.56 (0.79-3.08) 0.205
Prior HAART at hospital admission 0.78 (0.39-1.57) 0.5
HAART initiated during ICU stay 1.05 (0.32-3.44) 0.9
HAART use in ICU 1.12 (0.56-2.24) 0.7
HIV viral load (per 1-log copies/ml increase)
a 1.025 (0.83-1.26) 0.8
CD4 lymphocyte count (per 10-cells/mm
3 decrease)
b 1.033 (1.004-1.063) 0.027 1.036 (1.003-1.069) 0.033
Admission diagnosis
Respiratory failure 0.99 (0.50-1.95) 1.0
Interstitial pneumonitis with ground glass opacity 0.78 (0.39-1.57) 0.5
Sepsis (including bacterial pneumonia) 2.25 (1.08-4.69) 0.03 2.91 (1.11-7.62) 0.029
Hospitalization to ICU admission > 24 hours 2.72 (1.23-6.01) 0.013 2.21 (0.90-5.47) 0.085
Albumin (per 1 g/dl decrease)
c 1.69 (1.04-2.74) 0.034 1.31 (0.74-2.34) 0.36
The goodness of fit (Hossmer-Lemeshow Chisquare P value) was 0.619. 14 patients were not included in the multivariable model because of missing data.
aData were available for 121 ICU admissions.
bData were available for 129 ICU admissions.
cData were available for 127 ICU admissions.
CI, confidence interval; HAART, highly active antiretroviral therapy; MSM, men who have sex with men.
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count was 67 cells/mm
3 (IQR, 16-207 cells/mm
3). The
suboptimal treatment responses to HAART in these
patients may be due to the presence of transmitted drug
resistance of the HIV strains, poor adherence to antire-
troviral therapy prescribed that may result in emergence
of antiretroviral drug resistance mutations, and immu-
nologic non-response [31].
Lower serum albumin level has been found to be a
poor prognostic factor in the studies from San Fran-
cisco General Hospital [8,16]. In our study, we also
found that serum albumin level less than 2.8 g/dl is
associated with hospital mortality, although it is of no
statistical significance in multivariable analysis. Low
serum albumin level may be the results of poor nutri-
tional status and severe catabolism from the prolonged
critical illness, which may lead to insufficient intravas-
cular volume, hemodynamic instability, increased
extravascular lung water, and therefore, increased mor-
tality [33,34].
There are several limitations in this study. First, our
study is retrospective and observational in study design,
which may preclude us from identifying every possible
confounding factor. Second, the case number in this
study remains small and prospective studies of larger
case number are needed to examine the impact of
HAART and other parameters on the outcomes of HIV-
infected patients who require care in the ICU. Third,
the majority of our patients acquired HIV through sex-
ual contact and our findings may not be generalizable to
the health care facilities that provide HIV care to a
higher proportion of injecting drug users who are more
likely to develop bacterial complications due to use of
contaminated syringes, needles and diluent. Fourth, our
findings may not be generalizable to other hospitals
because the decisions of admissions to ICU in this refer-
ral hospital for HIV care depends on clinical assessment
of the treating physicians and consultations with the cri-
tical care specialists, which may vary among the hospi-
tals providing HIV care. Finally, we were not able to
Figure 1 Kaplan-Meier survival curves stratified by admission diagnosis of sepsis and CD4 lymphocyte count less than 50 cells/mm
3. P
value of log-rank test between the four groups is 0.003.
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City
[reference]
San Francisco
[8]
San Francisco [16] New York
[20]
Paris
[18]
Mexico
[14]
São Paulo
[15]
Rio de Janeiro
[19]
Taipei
Study year 1996-1999 2000-2004 1997-1999 1996-2005 1996-2006 1996-2006 2006-2008 2001-2010
HIV-related
characteristics
Newly
diagnosed HIV
(%)
5.6 - - 19.7
a 26 38 28 44.4
Median CD4
count (cells/
mm
3)
64 109 85 - - 39 75 30
ICU admission
diagnosis (%)
Respiratory
failure (%)
40.7 42.3 30.0 58.8 51.0 33.1 29 44.4
pneumocystosis
(%)
10.7 13.8 - 18.7 - 23.2 - 8.1
b
Sepsis (%) 11.9 20.3 13.0 23.9 26.0 31.2 20.5 33.3
Neurological
disease (%)
12.4 16.3 18.0 32 15.0 19.4 22.7 11.9
Others (%) 35.0 21.1 39.0 - 21.0 16.2 27.3 13.3
Mortality
predictors
ART use No prior HAART
univariably increased
hospital mortality, 1.8
(1.02-3.2), but not
significantly in
multivariable analysis
No association No association No association No prior
HAART
independently
increased ICU
mortality, 3.33
(1.43-10.0)
c
No ART use in
ICU
independently
increased 6-
month
mortality, 2.00
(1.41-2.86)
No association No association
CD4 count
(cells/mm3)
- - CD4 < 200 univariably
increased hospital
mortality, 2.24 (1.16-
4.31), but not
significantly in
multivariable analysis
No association - CD4 < 50
independently
increased ICU
mortality, 2.10
(1.17-3.76)
No association CD4 (per 10-cells/mm
3
decrease) independently
increased hospital mortality,
1.036 (1.003-1.069)
Admission
diagnosis of
sepsis
- No significant
difference between
with sepsis and
respiratory failure
- Severe sepsis
independently
increased ICU
mortality, 3.67
(1.53-8.80)
Septic shock
independently
increased ICU
mortality, 2.4
(1.1-5.2)
c
Sepsis
independently
increased ICU
mortality, 3.16
(1.65-6.06)
Severe sepsis/
septic shock
independently
increased 28-day
mortality, 3.13
(1.21-8.07)
c
Sepsis independently
increased hospital mortality,
2.91 (1.11-7.62)
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0Table 4 Comparisons of studies regarding HIV-infected patients admitted to ICU in the HAART era (Continued)
Hospital-to-ICU
interval
- - - Delayed ICU
admission
independently
increased ICU
mortality, 3.04
(1.29-7.71)
- - - Hospital-to-ICU interval > 24
hours univariably increased
hospital mortality, 2.72 (1.23-
6.01), but not significantly in
multivariable analysis
Serum albumin
level (g/dL)
Serum albumin < 2.6
independently
increased hospital
mortality, 3.5 (1.8-6.6)
Lower serum
albumin (per 1-g/dl
decrease)
independently
increased hospital
mortality, 2.08 (1.41-
3.06)
- - No association No association - Lower serum albumin (per 1-
g/dl decrease) univariably
increased hospital mortality,
1.69 (1.04-2.74), but not
significantly in multivariable
analysis
Values are given as odds ratio (95% confidence interval), unless otherwise indicated.
aHIV diagnosis within 60 days before ICU admission.
bDiagnosis was based on identification of Pneumocystis in the sputum, bronchoalveolar-lavage fluid, or transbronchoscopic or surgical lung biopsy.
cValues are given as hazard ratio (95% confidence interval).
ART, antiretroviral therapy; HAART, highly active antiretroviral therapy.
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0assess the adherence to antiretroviral therapy prescribed
in those patients who had been on HAART prior to
hospital admission, nor were we able to assess the bioa-
vailability of HAART that was initiated and continued
in those patients during the ICU stay.
Conclusions
In conclusion, we found respiratory failure remained the
most common cause of ICU admission for HIV-infected
patients in the era of HAART. The hospital mortality of
HIV-infected patients who were admitted to the ICU
was associated with low CD4 lymphocyte count and the
diagnosis of sepsis.
Key messages
￿ Respiratory failure is the most common cause of
ICU admission for HIV-infected patients in the era
of HAART, followed by sepsis and neurological
disease.
￿ The hospital mortality of HIV-infected patients
who are admitted to the ICU is associated with low
CD4 lymphocyte count and the diagnosis of sepsis.
￿ Low serum albumin level and delayed ICU admis-
sion are associated with poor outcome.
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